{"name": "gliquidone", "category": "drug", "content": "Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).   == Contraindications == Allergy to sulfonylureas or sulfonamides Diabetes mellitus type 1 Diabetic ketoacidosis Patients that underwent removal of the pancreas Acute porphyria Severe liver disease accompanying with liver insufficiency Several conditions (e.g., infectious diseases or major surgical intervention), when insulin administration is required Pregnancy or breastfeeding   == Pharmacokinetics == Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients with kidney disease and diabetic nephropathy.   == References =="}